Cooperative Agreement U01DD001069

Results Group LLC, in partnership with the Charcot-Marie-Tooth Association (CMTA) and CMT Centers of Excellence at Massachusetts General Hospital, St. Jude Hospital, and Children's Hospital of Colorado, received a $300,000 Project Grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR, CFDA 93.433) awarded June 1, 2025, with completion targeted for January 15, 2026. The six-month initiative addresses a critical treatment gap for youth with...

Federal Cooperative Agreement Summary The National Human Genome Research Institute (NHGRI) awarded a $125,000 Cooperative Agreement to Boston Children's Hospital under the Human Genome Research program (CFDA 93.172) effective September 20, 2025, with an ultimate completion date of August 31, 2030. This award supports the Spastic Paraplegia Centers of Excellence Research Network (SP-CERN) - Rare Disease Clinical Research Center (RDCRC), a collaborative consortium designed to accelerate the...

This Project Grant award of $305,447, issued on September 2, 2024 by the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research), aims to identify predictive biomarkers for acute intermittent hypoxia-induced motor recovery in individuals with incomplete spinal cord injury. The research team from the University of Colorado will: 1) Validate the cellular mechanisms underlying hypoxia-induced plasticity in humans, using...

The Children's Hospital Corporation, doing business as Boston Children's Hospital, received a $2,000 Project Grant award from the National Institutes of Health's John E. Fogarty International Center (CFDA 93.989 - International Research and Research Training) to study ATP1A3-related disorders in Brazil. The key goals of this 2-year project are to: Establish a large patient cohort in Brazil to study the genotype-phenotype correlation and natural history of ATP1A3-related disorders, which...

The Spinex Inc. was awarded a $4,719,091 Project Grant from the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases to develop and clinically validate a transcutaneous electrical spinal cord neuromodulation (TESCON) device to mitigate symptoms of neurogenic bladder resulting from spinal cord injury. The award, made under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support Spinex in building a commercial...

Federal Grant Award Summary The University of Colorado-Denver received a $776,754 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 15, 2025, with an ultimate completion date of April 30, 2030. This ancillary prospective longitudinal neurodevelopmental study, designated CAN-DO (COMPASS Ancillary Neurodevelopmental Outcomes), will evaluate long-term neurodevelopmental outcomes in neonates...

Federal Project Grant Award Summary The University of Texas Health Science Center at Houston received a $620,820 project grant awarded August 1, 2025, through the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). This five-year award, extending through July 31, 2030, supports a Phase III clinical trial evaluating the efficacy of cryopreserved human umbilical cord (HUC) grafts as meningeal...

Federal Cooperative Agreement Summary Emory University received an $830,887 Cooperative Agreement award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective September 15, 2025, with completion anticipated by August 31, 2030. The award supports ARISEN (Autoimmunity, Rasmussen's, Inflammation & Status Epilepticus Research Network), the first U.S.-based multi-center registry...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $178,000.00 to The Children's Hospital of Philadelphia (CHOP) to design and validate a Pelizaeus Merzbacher Disease (PMD) severity scale. The goal is to develop a clinician-reported outcome measure that can be used to stratify PMD patients by disease severity, particularly early in the disease...

Federal Cooperative Agreement Summary Cincinnati Children's Hospital Medical Center received a $3.24M Cooperative Agreement award from the National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective February 9, 2026 through December 31, 2030. The Cincinnati Advanced NAM Development and Operational Research Center (CANDOR) will develop combinatorial New Approach Methodologies (NAMs) to more accurately model gastrointestinal diseases...